Fig. 1

KMT2 family mutations predicted better clinical outcomes in the ICI-treated cohort. A Scale stacked column chart of the mutation status of the KMT2 family in the TCGA pan-cancer cohort. B K-M curve shows the difference of OS between patients with and without KMT2 family mutations in the TCGA pan-cancer cohort. C K-M curves show the difference of OS between patients with and without KMT2 family mutations in the ICI-treated cohort (n = 2069). D Patients with KMT2 family mutations exhibited a high ORR while receiving ICI therapy. E K-M curves show the difference of PFS between patients with and without KMT2 family mutations in the ICI-treated cohort. F Patients with KMT2 family mutations exhibited high ORRs and DCBs while receiving ICI therapy. G The TMB levels for patients with and without KMT2 family mutations in the ICI-treated cohort (n = 2069), Non-silent and silent mutation rates of patients with and without KMT2 family mutations in the TCGA pan-cancer cohort. H The mRNA expression levels of three immune checkpoints (PDCD1, CD274, CTLA-4) for patients with and without KMT2 family mutations in the TCGA pan-cancer cohort. I, J OS- or PFS-related univariate and multivariate Cox regression analyses revealed that KMT2 family mutations are a potential independent predictor for the prognosis of patients receiving ICI therapy